January 15, 2021 – A noninvasive multimodal blood test demonstrated high sensitivity and specificity for the detection of colorectal advanced neoplasia, according to prospective study results presented at Gastrointestinal Cancers Symposium.

MedScape | June 01, 2020 A blood test detected 11 of 11 cases of colorectal cancer in a study involving 354 patients, and also spotted a majority of cases — 40 out of 53 — in which participants had advanced adenomas, an investigator said.

OncLive | May 08, 2020 The multimodal FirstSight^CRC blood test demonstrated higher sensitivity and specificity than standard screening protocols in detecting advanced adenomas and colorectal cancer (CRC), explained Shai Friedland, MD, who added that the noninvasive assay could lead to improved screening compliance.

NEW YORK (GenomeWeb) – Researchers shared new data this week from a study of the colorectal cancer screening test being developed by CellMax life, providing the first prospective sensitivity and specificity evidence for the assay in an intended use population in the US.

MedPage Today | May 7, 2020 Testing blood for three distinct colorectal cancer (CRC) markers showed perfect sensitivity and 90% specificity for detecting malignancy in a preliminary study, researchers said.

Healio Gastroenterology | May 6, 2020 A novel, blood-based assay improved the detection of advanced and non-advanced adenomas by analyzing cell-free DNA and circulating gastrointestinal epithelial cells, according to research from Digestive Disease Week.

Becker’s Hospital Review | May 04, 2020 CellMax Life released results from its U.S. study of the FirstSight blood test that revealed the test detected colorectal cancer with 100 percent sensitivity at 90 percent specificity.